CenterForBiosimilars

@BiosimCenter

Your Resource for Emerging Therapies.

Cranbury, NJ
Vrijeme pridruživanja: travanj 2016.

Tweetovi

Blokirali ste korisnika/cu @BiosimCenter

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BiosimCenter

  1. Reference-based drug pricing increased the use of lower-cost therapies, according to new study.

    Poništi
  2. 4. velj
    Poništi
  3. 4. velj
    Poništi
  4. 3. velj
    Poništi
  5. 3. velj
    Poništi
  6. 2. velj
    Poništi
  7. 2. velj
    Poništi
  8. 2. velj
    Poništi
  9. 1. velj

    Experts in the field of wrap up their discussion by considering what must be done to educate pharmacists, nurses, and patients.

    Poništi
  10. 1. velj

    What's happening in the world of ? Check out our top 5 news items for the week

    Poništi
  11. 1. velj
    Poništi
  12. 31. sij
    Poništi
  13. 30. sij

    A recent paper work looked at biosimilar lentivirus-based , which showed successful and prolonged expression of the recombinant antibody in rats.

    Poništi
  14. 30. sij
    Poništi
  15. 29. sij

    A recently column looks at the global market from the perspective of patients and physicians; what does it mean that different regulatory bodies have different standards in place for approval?

    Poništi
  16. 29. sij

    The FDA anticipates many more gene product approvals, saying there are more than 900 investigational new drug (IND) applications for ongoing clinical studies.

    Poništi
  17. 27. sij
    Poništi
  18. 26. sij
    Poništi
  19. 26. sij
    Poništi
  20. 26. sij

    From this week's Specialty Therapies and Biosimilars Congress: expert shares why IPI could be a killer for new drug investment

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·